BCL-2 is overexpressed in leukemia stem cells and the use of a specific inhibitor of BCL-2, venetoclax, combined with azacitidine, resulted in disease remission in acute myeloid leukemia by CSC targeting [36,37]. Here, BCL2 is linked to acute myeloid leukemia.